ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

Last updated: January 15, 2026
Sponsor: Stratpharma AG
Overall Status: Active - Recruiting

Phase

4

Condition

Vaginitis

Vaginal Atrophy

Treatment

7-940

Clinical Study ID

NCT07346287
SPAMG08
  • Ages > 18
  • Female

Study Summary

Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed vaginal atrophy

  • Access to smartphone and tablet, laptop or computer

  • Access to a valid email address

  • Previously completed laser therapy session schedule

Exclusion

Exclusion Criteria:

  • Unable to provide informed consent

  • Patient unable to apply topical device

  • Allergy or intolerance to ingredients or excipients of the formulation of studiedproducts

  • Systemic hormonal or steroidal therapy started less than 30 days before baseline ( =not yet on a stable regimen)

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: 7-940
Phase: 4
Study Start date:
August 13, 2025
Estimated Completion Date:
April 30, 2026

Connect with a study center

  • Orange Coast Women's Medical Group

    Laguna Hills 5364306, California 5332921 92653
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.